Mark Talamonti to Safety
This is a "connection" page, showing publications Mark Talamonti has written about Safety.
Connection Strength
0.084
-
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006 Feb; 13(2):150-8.
Score: 0.063
-
Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010 Jun 01; 101(7):587-92.
Score: 0.021